Nearly 30 life science SPAC deals have closed or announced definitive agreements within the past year, helping private companies access new capital and public markets quickly. However, even recent traditions in SPAC deal terms continue to evolve because of statements from regulators regarding the accounting for warrants, shifts in investor expectations, and the availability of PIPE deal supporters, among other factors. Join this webinar to learn best practices for negotiating SPAC deal terms in today’s market to maximize raising capital to serve biomedical innovation. Interact with the below dealmaking experts to ask them your own questions during the session.

Find out more and register.